1. EGFR Inhibitors Plus Bevacizumab are Superior Than EGFR Inhibitors Alone as First-Line Setting in Advanced NSCLC With EGFR Mutations and BIM Deletion Polymorphisms (BIM-CLICaP).
- Author
-
Cardona, Andrés F., Ordóñez-Reyes, Camila, Ruiz-Patiño, Alejandro, Garcia-Robledo, Juan Esteban, Barron, Lucia Zatarain, Recondo, Gonzalo, Rojas, Leonardo, Corrales, Luis, Martín, Claudio, Barrón, Feliciano, Sotelo, Carolina, Rodríguez, July, Ricaurte, Luisa, Rolfo, Christian, Ávila, Jenny, Mayorga, Diana, Archila, Pilar, Otero, Jorge, Mas, Luis, and Bermudez, Maritza
- Subjects
- *
EPIDERMAL growth factor receptors , *DELETION mutation , *INTRONS , *NON-small-cell lung carcinoma , *DNA sequencing , *OVERALL survival - Abstract
PURPOSE: BIM activation is essential for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)–triggered apoptosis in EGFR -mutant non–small-cell lung cancer (NSCLC). A deletion in the intron two of the BIM gene results in generation of alternatively spliced isoforms that impairs their apoptotic response to TKIs, conferring the NSCLC cells intrinsic resistance to these medications. Patients with both alterations have poor clinical evolution. The current study aimed to investigate the clinical efficacy and tolerability of EGFR-TKIs plus bevacizumab (Bev) versus EGFR-TKIs alone as first-line treatment in advanced NSCLC patients with EGFR mutations and BIM deletions (BIMdel). MATERIALS AND METHODS: A retrospective analysis was conducted. BIMdel was detected using polymerase chain reaction analysis and direct sequencing of DNA. BIM protein expression was investigated by immunohistochemistry, and BIM mRNA levels by reverse transcriptase-polymerase chain reaction. Clinical characteristics, overall survival, progression-free survival (PFS), overall response rate (ORR), and treatment-related adverse events were compared between both groups. RESULTS: Thirty-three patients were included; 15 received EGFR-TKIs, and 18 received EGFR-TKIs plus Bev. The median age was 63 years, with a majority of recruited female patients. All included individuals had an Eastern Cooperative Oncology Group performance score of 2 or less. The addition of Bev resulted in a significantly higher ORR (94.4% v 40%, P >.001). Median PFS was longer with the use of the combination therapy (11.12 v 7.87 months; P =.001). Median overall survival tended to be longer in the EGFR-TKIs plus Bev (30.9 v 25.4 months; P =.06) but failed to reach statistical significance. Response in terms of both partial and complete as well as overall favorably affected PFS. CONCLUSION: EGFR-TKIs plus Bev conferred a significantly higher ORR and PFS in advanced NSCLC patients with EGFR mutation and BIMdel. Further prospective studies are needed to validate these findings. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF